Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden

Paolo Dapavoa Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, ItalyView further author information

Martina Burlandob Clinica Dermatologica Ospedale Policlinico San Martino - IRCCS, Università di Genova, Genova, ItalyView further author information

Claudio Guarneric Department of Biomedical and Dental Sciences and Morpho Functional Imaging, University of Messina, Messina, ItalyView further author information

Matteo Megnad Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information

Alessandra Narcisie Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Rozzano, Italy;f Department of Biomedical sciences, Humanitas University, Milan, Pieve Emanuele, ItalyView further author information

Marina Talamontig Dermatology Unit, Fondazione Policlinico “Tor Vergata”, Rome, ItalyView further author information

Paolo Gisondih Dermatology and Venereology, Department of Medicine, University of Verona, Verona, ItalyCorrespondence[email protected]

https://orcid.org/0000-0002-1777-9001 View further author information

show all

Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date